Abbott/Anesta Fentanyl Oralet promotion and distribution should become less restrictive -- FDA committee.
Executive Summary
FENTANYL ORALET PROMO, DISTRIBUTION SHOULD BECOME LESS RESTRICTIVE, FDA's Anesthetic & Life Support Drugs Advisory Committee recommended Dec. 12. The committee unanimously agreed that promotion of the Abbott/Anesta narcotic analgesic (oral transmucosal fentanyl) should be allowed to extend to journal advertising and that distribution should go through the typical channels of wholesalers and distribution centers. "I personally can't see any benefit in putting such a restriction on the sponsor" for distribution and promotion, committee Chairman John Downs, MD, University of South Florida College of Medicine, said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth